Protara Therapeutics, Inc. (TARA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.49
- As of
Kresmion compiles this page from TARA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Protara Therapeutics, Inc. (TARA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
See the full TARA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TARA on one page. Preview it with sample data, then open it live with a free account.
Preview the TARA dossierActive events for TARA
- high13F: funds added
3 tracked funds increased TARA this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 8.4%, EPS $-0.36 vs $-0.3322 estimate
- high13F: funds added
4 tracked funds increased TARA this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +4078% to TARA (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 52% of TARA (2026Q2)
FREE, NO ACCOUNT
Every event on TARA, as it fires
You are seeing 5 of 15 events recorded on TARA since 2026-06-05.
The five above landed across 3 days. The other 10 were recorded on 2 other days. 8 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TARA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 74365U107 · 2026Q2 | $11.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 74365U107 · 2026Q2 | $4.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 74365U107 · 2026Q2 | $2.1M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 74365U107 · 2026Q2 | $961K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 74365U107 · 2026Q2 | $266K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 74365U107 · 2026Q2 | $42K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TARA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TARA against its peers
TARA's return on equity of -29.2% ranks in the 81st percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | TARA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 2.0M | n/a | 11 |
| Operating margin | n/a | -279.5% | n/a | 7 |
| Net margin | n/a | -240.3% | n/a | 7 |
| Return on equity | -29.2% | -76.7% | 81 | 17 |
Peers (20): SPRB, NKTX, ANTX, CUE, ORGO, ARMP, MSLE, CMPX, HURA, AVXL, MOLN, HUMA, ABOS, MGNX, FHTX, MENS, CNTN, UPB, NBP, NGEN. Left out: RNA (no annual filing), OTLK (no annual filing), RTSN (no annual filing), TLSA (period gap), VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TARA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TARA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TARA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.